secwatch.observer — SEC 8-K summary
======================================

Issuer:     bioAffinity Technologies, Inc. (BIAF)
CIK:        0001712762
Form:       8-K
Filed at:   2026-06-30T21:19:20+00:00
Accession:  0001493152-26-031327
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

bioAffinity reports 300% YoY CyPath Lung sales growth in April; partners with Philips for veteran screening
--------------------------------------------------------------------------------

- CyPath Lung unit sales in April 2026 increased nearly 300% vs. April 2025; ordering physician sites up 69% Q1 2025 to Q1 2026.
- Collaboration with Philips to enhance lung cancer screening for U.S. veterans using mobile CT, CyPath Lung, and 4DMedical software.
- Pilot study with Brooke Army Medical Center underway for asthma/COPD companion diagnostics using flow cytometry+AI.
- Preclinical research shows siRNA silencing selectively kills squamous skin cancer cells, suggesting topical treatment for basal/squamous cell carcinomas.
- Recent news includes Mexico patent allowance for CyPath Lung technology and record monthly sales in April 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1712762/000149315226031327/0001493152-26-031327-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1712762/000149315226031327/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-031327

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer